Boston Scientific's Total Assets for the quarter that ended in Mar. 2026 was MXN799,768 Mil.
During the past 12 months, Boston Scientific's average Total Assets Growth Rate was 8.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 9.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 9.50% per year.
During the past 13 years, Boston Scientific's highest 3-Year average Total Assets Growth Rate was 80.20%. The lowest was -11.30%. And the median was 11.55%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Boston Scientific's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Boston Scientific Total Assets Related Terms
Boston Scientific Total Assets Historical Data
* Premium members only.
The historical data trend for Boston Scientific's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Boston Scientific's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific (MEX:BSX) has a Total Assets of MXN799,768 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Boston Scientific and its competitors.
Is Boston Scientific's Total Assets too high?
Boston Scientific's current Total Assets is MXN799,768 Mil. Overall, Boston Scientific has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Total Assets compare to EW and GEHC?
Boston Scientific's Total Assets of MXN799,768 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Boston Scientific and its competitors. Boston Scientific's current Total Assets is MXN799,768 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,849.32, compared to a current price of MXN784.12 — trading 57.6% below its estimated fair value. The current Total Assets is MXN799,768 Mil. Boston Scientific's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current Total Assets is MXN799,768 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (MEX:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of MXN784.12 is trading 57.6% below its estimated GF Value™ of MXN1,849.32.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for MEX:BSX:
Total Assets: MXN799,768 Mil
GF Value™: MXN1,849.32 vs. price of MXN784.12 (57.6% below fair value)
No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
85GF Score
Get the complete analysis for MEX:BSX
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BSX has been successfully added to your 
